Since venetoclax and navitoclax are both BCL2 inhibitors, Through analysis of the BEAT-AML database and Lee et al.’s database, we predicted that the SF-res population was more sensitive to BCL2 inhibition. The gene discussed is BCL2; the disease is acute myeloid leukemia.